CY1125039T1 - Νεα χρηση του ν,ν-δις-2-μερκαπτοαιθυλ ισοφθαλαμιδιου - Google Patents
Νεα χρηση του ν,ν-δις-2-μερκαπτοαιθυλ ισοφθαλαμιδιουInfo
- Publication number
- CY1125039T1 CY1125039T1 CY20221100175T CY221100175T CY1125039T1 CY 1125039 T1 CY1125039 T1 CY 1125039T1 CY 20221100175 T CY20221100175 T CY 20221100175T CY 221100175 T CY221100175 T CY 221100175T CY 1125039 T1 CY1125039 T1 CY 1125039T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bis
- new use
- mercaptoethyl isophthalamide
- isophthalamide
- mercaptoethyl
- Prior art date
Links
- QZUPTXGVPYNUIT-UHFFFAOYSA-N isophthalamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1 QZUPTXGVPYNUIT-UHFFFAOYSA-N 0.000 title 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229960005489 paracetamol Drugs 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 231100000419 toxicity Toxicity 0.000 abstract 2
- 230000001988 toxicity Effects 0.000 abstract 2
- YJPRSARATKALKH-UHFFFAOYSA-N 3-n,3-n-bis(2-sulfanylethyl)benzene-1,3-dicarboxamide Chemical compound NC(=O)C1=CC=CC(C(=O)N(CCS)CCS)=C1 YJPRSARATKALKH-UHFFFAOYSA-N 0.000 abstract 1
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201613535 | 2016-08-05 | ||
| PCT/GB2017/052306 WO2018025049A1 (en) | 2016-08-05 | 2017-08-04 | New use of n,n-bis-2-mercaptoethyl isophthalamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125039T1 true CY1125039T1 (el) | 2023-03-24 |
Family
ID=60202272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100175T CY1125039T1 (el) | 2016-08-05 | 2022-03-01 | Νεα χρηση του ν,ν-δις-2-μερκαπτοαιθυλ ισοφθαλαμιδιου |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20190240173A1 (enExample) |
| EP (2) | EP4029497A1 (enExample) |
| JP (1) | JP6926192B2 (enExample) |
| KR (1) | KR102538388B1 (enExample) |
| CN (1) | CN109562179A (enExample) |
| AU (1) | AU2017305661B2 (enExample) |
| BR (1) | BR112019002130A2 (enExample) |
| CL (1) | CL2019000229A1 (enExample) |
| CY (1) | CY1125039T1 (enExample) |
| DK (1) | DK3493849T3 (enExample) |
| EA (1) | EA201990443A1 (enExample) |
| ES (1) | ES2907838T3 (enExample) |
| HR (1) | HRP20220252T1 (enExample) |
| HU (1) | HUE057782T2 (enExample) |
| IL (1) | IL264538B2 (enExample) |
| LT (1) | LT3493849T (enExample) |
| MA (1) | MA45855B1 (enExample) |
| MD (1) | MD3493849T2 (enExample) |
| MX (1) | MX387853B (enExample) |
| MY (1) | MY199733A (enExample) |
| NZ (1) | NZ750271A (enExample) |
| PH (1) | PH12019500237A1 (enExample) |
| PL (1) | PL3493849T3 (enExample) |
| PT (1) | PT3493849T (enExample) |
| RS (1) | RS62924B1 (enExample) |
| SG (1) | SG11201900565RA (enExample) |
| SI (1) | SI3493849T1 (enExample) |
| SM (1) | SMT202200109T1 (enExample) |
| UA (1) | UA125394C2 (enExample) |
| WO (1) | WO2018025049A1 (enExample) |
| ZA (1) | ZA201900594B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005057D0 (en) | 2020-04-06 | 2020-05-20 | Emeramed Ltd | New Use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586600B2 (en) | 2000-12-06 | 2003-07-01 | University Of Kentucky Research Foundation | Multidentate sulfur-containing ligands |
| US8950583B2 (en) * | 2008-12-06 | 2015-02-10 | Ermes Medical Company Limited | Method to remove heavy metals from a mammal |
| US20120122787A1 (en) * | 2009-07-10 | 2012-05-17 | Rong Li | Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases |
| US8575218B2 (en) | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| AU2010297933A1 (en) | 2009-09-28 | 2012-04-19 | University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use |
| US8426368B2 (en) | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
| US20110237776A1 (en) | 2010-03-25 | 2011-09-29 | Haley Boyd E | Aromatic compounds with sulfur containing ligands |
-
2017
- 2017-08-04 EP EP21211493.8A patent/EP4029497A1/en not_active Withdrawn
- 2017-08-04 MA MA45855A patent/MA45855B1/fr unknown
- 2017-08-04 LT LTEPPCT/GB2017/052306T patent/LT3493849T/lt unknown
- 2017-08-04 MY MYPI2019000127A patent/MY199733A/en unknown
- 2017-08-04 RS RS20220147A patent/RS62924B1/sr unknown
- 2017-08-04 JP JP2019505490A patent/JP6926192B2/ja active Active
- 2017-08-04 US US16/318,842 patent/US20190240173A1/en not_active Abandoned
- 2017-08-04 MD MDE20190671T patent/MD3493849T2/ro unknown
- 2017-08-04 HR HRP20220252TT patent/HRP20220252T1/hr unknown
- 2017-08-04 EA EA201990443A patent/EA201990443A1/ru unknown
- 2017-08-04 WO PCT/GB2017/052306 patent/WO2018025049A1/en not_active Ceased
- 2017-08-04 DK DK17793720.8T patent/DK3493849T3/da active
- 2017-08-04 BR BR112019002130-2A patent/BR112019002130A2/pt not_active Application Discontinuation
- 2017-08-04 MX MX2019000978A patent/MX387853B/es unknown
- 2017-08-04 AU AU2017305661A patent/AU2017305661B2/en active Active
- 2017-08-04 NZ NZ750271A patent/NZ750271A/en unknown
- 2017-08-04 EP EP17793720.8A patent/EP3493849B1/en active Active
- 2017-08-04 CN CN201780046065.1A patent/CN109562179A/zh active Pending
- 2017-08-04 PT PT177937208T patent/PT3493849T/pt unknown
- 2017-08-04 KR KR1020197003227A patent/KR102538388B1/ko active Active
- 2017-08-04 ES ES17793720T patent/ES2907838T3/es active Active
- 2017-08-04 UA UAA201902172A patent/UA125394C2/uk unknown
- 2017-08-04 PL PL17793720T patent/PL3493849T3/pl unknown
- 2017-08-04 HU HUE17793720A patent/HUE057782T2/hu unknown
- 2017-08-04 SM SM20220109T patent/SMT202200109T1/it unknown
- 2017-08-04 SI SI201731094T patent/SI3493849T1/sl unknown
- 2017-08-04 SG SG11201900565RA patent/SG11201900565RA/en unknown
-
2019
- 2019-01-28 ZA ZA2019/00594A patent/ZA201900594B/en unknown
- 2019-01-29 IL IL264538A patent/IL264538B2/en unknown
- 2019-01-29 CL CL2019000229A patent/CL2019000229A1/es unknown
- 2019-02-01 PH PH12019500237A patent/PH12019500237A1/en unknown
-
2022
- 2022-03-01 CY CY20221100175T patent/CY1125039T1/el unknown
-
2024
- 2024-12-06 US US18/972,315 patent/US20250325503A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CO2018004750A2 (es) | Composiciones para inhibir la actividad arginasa | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| CY1120173T1 (el) | Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης | |
| EA201892128A1 (ru) | Гетероциклические амиды, полезные в качестве модуляторов | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| AR101995A1 (es) | COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6 | |
| UY35821A (es) | Compuesto heterocíclico | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CR20160418A (es) | Nuevos compuestos biciclicos de 7 eslabones | |
| CR20170315A (es) | Inhibridores bace 1 selectivos | |
| AR105967A1 (es) | Sales de un inhibidor de pim quinasa | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| CL2016001349A1 (es) | Uso de derivados de bencimidazol-prolina | |
| EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
| EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| MX383577B (es) | Derivados sustituidos de guanidina. | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| EA202091169A1 (ru) | Применяемые в качестве ингибиторов iap миметики smac и их применение |